keyword
MENU ▼
Read by QxMD icon Read
search

minsig choi

keyword
https://www.readbyqxmd.com/read/27618106/clinical-utility-of-positron-emission-tomography-magnetic-resonance-imaging-pet-mri-in-gastrointestinal-cancers
#1
REVIEW
Robert Matthews, Minsig Choi
Anatomic imaging utilizing both CT (computed tomography) and MRI (magnetic resonance imaging) limits the assessment of cancer metastases in lymph nodes and distant organs while functional imaging like PET (positron emission tomography) scan has its limitation in spatial resolution capacity. Hybrid imaging utilizing PET-CT and PET-MRI are novel imaging modalities that are changing the current landscape in cancer diagnosis, staging, and treatment response. MRI has shown to have higher sensitivity in soft tissue, head and neck pathology, and pelvic disease, as well as, detecting small metastases in the liver and bone compared to CT...
September 9, 2016: Diagnostics
https://www.readbyqxmd.com/read/27284473/neoadjuvant-vs-adjuvant-treatment-of-siewert-type-ii-gastroesophageal-junction-cancer-an-analysis-of-data-from-the-surveillance-epidemiology-and-end-results-seer-registry
#2
Joseph A Miccio, Oluwadamilola T Oladeru, Jie Yang, Yaqi Xue, Minsig Choi, Yue Zhang, Hannah Yoon, Samuel Ryu, Alexander M Stessin
BACKGROUND: Cancer of the gastroesophageal junction (GEJ) has been rising in incidence in recent years. The role of radiation therapy (RT) in the treatment of GEJ cancer remains unclear, as the largest prospective trials advocating for either adjuvant or neoadjuvant chemoradiotherapy (CRT) combine GEJ cancer with either gastric or esophageal cancer. The aim of the present study is to examine the association of neoadjuvant versus adjuvant treatment with overall and disease-specific survival (DSS) for patients with surgically resected cancer of the true GEJ (Siewert type II)...
June 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/27118441/a-randomized-phase-ii-trial-of-cetuximab-with-or-without-px-866-an-irreversible-oral-phosphatidylinositol-3-kinase-inhibitor-in-patients-with-metastatic-colorectal-carcinoma
#3
Daniel W Bowles, Mark Kochenderfer, Allen Cohn, Lucas Sideris, Nghia Nguyen, Vivian Cline-Burkhardt, Ian Schnadig, Minsig Choi, Lisle Nabell, Arvind Chaudhry, Robert Ruxer, Antonio Ucar, Diana Hausman, Luke Walker, Alexander Spira, Antonio Jimeno
BACKGROUND: The phosphotidylinositol-3 kinase (PI3K)/serine-threonine kinase/mammalian target of rapamycin signaling pathway is frequently altered in colorectal cancer (CRC). PX-866 is an oral, irreversible, pan-isoform inhibitor of PI3K. This randomized phase II study evaluated cetuximab with or without PX-866 in patients with metastatic, anti-epidermal growth factor receptor-naive, KRAS codon 12 and 13 wild-type CRC. PATIENTS AND METHODS: Patients with metastatic CRC who had received both oxaliplatin and irinotecan were randomized (1:1) to cetuximab (400 mg/m(2) loading then 250 mg/m(2) weekly) with or without PX-866 (8 mg orally daily; arms A and B, respectively)...
March 31, 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/26483065/second-line-treatment-of-advanced-gastric-cancer-where-do-we-stand
#4
REVIEW
Amit Mahipal, Minsig Choi, Richard Kim
Gastric cancer is a leading cause of cancer death and is associated with poor prognosis. The treatment of advanced gastric cancer is changing with the development of novel agents. Until recently, no standard treatment was available for patients with advanced gastric cancer in the second-line setting. Single-agent chemotherapy with docetaxel or irinotecan has been shown to improve survival and quality of life in patients whose disease has progressed while on prior chemotherapy. Combination chemotherapy is associated with a modest benefit at the expense of increased toxicity...
October 2015: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/26374557/immune-therapy-in-pancreatic-cancer-now-and-the-future
#5
REVIEW
Yue Zhang, Minsig Choi
Pancreatic cancer continues to be the most lethal malignancy with rising incidence. Traditional chemotherapy remains the standard treatment for advanced pancreatic cancer. Regimens like FOLFIRINOX (5-FU, leucovorin, irinotecan, and oxaliplatin) or gemcitabine and nab-paclitaxel have been used to palliate symptoms and prolong survival. Immune therapy is changing the current treatment paradigm for malignancy, especially with the recent development of antibodies that can modulate immune checkpoint pathways. Immunotherapy to treat pancreatic cancer is a promising approach due to its low toxicity and potential for creating life- long immune response...
2015: Reviews on Recent Clinical Trials
https://www.readbyqxmd.com/read/25621178/percutaneous-cryoablation-of-metastatic-lesions-from-colorectal-cancer-efficacy-and-feasibility-with-survival-and-cost-effectiveness-observations
#6
Hyun J Bang, Peter J Littrup, Brandt P Currier, Dylan J Goodrich, Minsig Choi, Lance K Heilbrun, Allen C Goodman
PURPOSE: To assess feasibility, complications, local tumor recurrences, overall survival (OS) and estimates of cost-effectiveness for multi-site cryoablation (MCA) of oligo-metastatic colorectal cancer (mCRC) in a prospective study. MATERIALS AND METHODS: 111 CT and/or US-guided percutaneous MCA procedures were performed on 151 tumors in 59 oligo mCRC patients. Mean patient age was 63 years (range 21-92 years), consisting of 29 males and 30 females. Tumor location was grouped according to common metastatic sites...
2012: ISRN Minimally Invasive Surgery
https://www.readbyqxmd.com/read/25481195/pet-scans-as-a-predictive-marker-of-survival-in-advanced-colorectal-cancer
#7
Minsig Choi, Sri Lakshmi S Kollepara, Lance K Heilbrun, Daryn Smith, Anthony F Shields, Philip A Philip
BACKGROUND: The clinical utility of fluorodeoxyglucose (FDG)-positron emission tomography (PET) scan in predicting the outcome of patients with metastatic colorectal cancer (mCRC) has not been well studied. We hypothesized that standardized uptake value (SUV) in FDG-PET scans after treatment predicts outcomes among patients with mCRC. PATIENTS AND METHODS: We retrospectively reviewed mCRC patients who had FDG-PET scans before their treatment and measured their SUV on follow-up imaging at the Karmanos Cancer Institute...
March 2015: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/25441058/multi-institutional-phase-i-study-of-low-dose-ultra-fractionated-radiotherapy-as-a-chemosensitizer-for-gemcitabine-and-erlotinib-in-patients-with-locally-advanced-or-limited-metastatic-pancreatic-cancer
#8
MULTICENTER STUDY
Andre Konski, Joshua E Meyer, Michael Joiner, Michael J Hall, Philip Philip, Anthony Shields, Erin McSpadden, Minsig Choi, Beth Adaire, Gail Duncan, Neal J Meropol, Terrence P Cescon, Steven J Cohen
PURPOSE: Gemcitabine (G) has been shown to sensitize pancreatic cancer to radiotherapy but requires lower doses of G and thus delays aggressive systemic treatment, potentially leading to distant failure. We initiated a phase I trial combining ultra-fractionated low-dose radiotherapy with full dose G and erlotinib in the treatment of patients with advanced pancreatic cancer. METHODS: Patients with locally advanced or metastatic pancreatic cancer confined to the abdomen and an ECOG performance status (PS) of 0-1 who had received 0-1 prior regimens (without G or E) and no prior radiotherapy were eligible...
October 2014: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/25008236/ipilimumab-augments-antitumor-activity-of-bispecific-antibody-armed-t-cells
#9
Hiroshi Yano, Archana Thakur, Elyse N Tomaszewski, Minsig Choi, Abhinav Deol, Lawrence G Lum
BACKGROUND: Ipilimumab is an antagonistic monoclonal antibody against cytotoxic T-lymphocyte antigen-4 (CTLA-4) that enhances antitumor immunity by inhibiting immunosuppressive activity of regulatory T cells (Treg). In this study, we investigated whether inhibiting Treg activity with ipilimumab during ex vivo T cell expansion could augment anti-CD3-driven T cell proliferation and enhance bispecific antibody (BiAb)-redirected antitumor cytotoxicity of activated T cells (ATC). METHODS: PBMC from healthy individuals were stimulated with anti-CD3 monoclonal antibody with or without ipilimumab and expanded for 10-14 days...
July 9, 2014: Journal of Translational Medicine
https://www.readbyqxmd.com/read/24833861/neo-adjuvant-therapy-for-hepatocellular-carcinoma-before-liver-transplantation-where-do-we-stand
#10
Masato Fujiki, Federico Aucejo, Minsig Choi, Richard Kim
Liver transplantation (LT) for hepatocellular carcinoma (HCC) within Milan criteria is a widely accepted optimal therapy. Neo-adjuvant therapy before transplantation has been used as a bridging therapy to prevent dropout during the waiting period and as a down-staging method for the patient with intermediate HCC to qualify for liver transplantation. Transarterial chemoembolization and radiofrequency ablation are the most commonly used method for locoregional therapy. The data associated with newer modalities including drug-eluting beads, radioembolization with Y90, stereotactic radiation therapy and sorafenib will be discussed as a tool for converting advanced HCC to LT candidates...
May 14, 2014: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/24674412/women-at-increased-risk-for-cardiac-toxicity-following-chemoradiation-therapy-for-esophageal-carcinoma
#11
Lauren M Tait, Joshua E Meyer, Erin McSpadden, Jonathan D Cheng, Frank A Baciewicz, Neal J Meropol, Steven J Cohen, Antoinette J Wozniak, Minsig Choi, Andre A Konski
PURPOSE: The purpose of this study was to identify factors associated with cardiac toxicity in patients treated with chemoradiation therapy (CRT) for esophageal carcinoma. METHODS AND MATERIALS: One hundred twenty-seven patients with adenocarcinoma or squamous cell carcinoma of the esophagus treated from July 2002 to June 2011 at 2 academic institutions with preoperative or definitive CRT were retrospectively reviewed. Association of cardiac toxicity with a number of variables was investigated, including heart disease, cardiac bypass and angioplasty, diabetes, insulin use, smoking, chemotherapy regimen, and tumor location...
October 2013: Practical Radiation Oncology
https://www.readbyqxmd.com/read/24618429/is-there-a-role-for-second-line-therapy-in-advanced-pancreatic-cancer
#12
Minsig Choi, Muhammad Wasif Saif, Richard Kim
FOLFIRINOX (5-FU, oxaliplatin and irinotecan) and gemcitabine based regimens are widely used for the first-line treatment for patients with advanced pancreatic adenocarcinoma. Nab-paclitaxel and gemcitabine has replaced the use of many single agent gemcitabine in these patients population. In patients who progress on the first line therapy use of either 5-FU, leucovorin and oxaliplatin (FOLFOX) or gemcitabine and nab-paclitaxel combination has become a de facto standard depending on the chemotherapy they received in first line...
March 2014: JOP: Journal of the Pancreas
https://www.readbyqxmd.com/read/24523592/nab-paclitaxel-potential-for-the-treatment-of-advanced-pancreatic-cancer
#13
REVIEW
Marwan Al-Hajeili, Asfar S Azmi, Minsig Choi
Advanced pancreatic adenocarcinoma is a deadly disease and is considered incurable. For the past two decades, gemcitabine remained the major chemotherapeutic drug with modest clinical benefit. Many chemotherapy and targeted agents were combined with gemcitabine but failed to demonstrate improvement in pancreatic cancer (PC) survival. Taxanes (paclitaxel, docetaxel) were introduced in the clinic as anti-microtubule agents and showed activity against PC cells in vitro; however, clinical efficacy was limited. Nab-paclitaxel (Abraxane) is an albumin-bound paclitaxel that has shown clinical activity in advanced breast and lung cancer...
2014: OncoTargets and Therapy
https://www.readbyqxmd.com/read/24167742/radiographic-parameters-in-predicting-outcome-of-patients-with-hepatocellular-carcinoma-treated-with-yttrium-90-microsphere-radioembolization
#14
Mohamed E Salem, Nitin Jain, Gregory Dyson, Stephanie Taylor, Sherif M El-Refai, Minsig Choi, Anthony F Shields, Jeffery Critchfield, Philip A Philip
Background. In patients with hepatocellular carcinoma, selection criteria for transarterial hepatic selective internal radiotherapy are imprecise. Additionally, radiographic parameters to predict outcome of transarterial hepatic selective internal radiotherapy have not been fully characterized. Patients and methods. Computed tomography (CT) scans of 23 patients with unresectable primary hepatocellular carcinoma before and after transarterial hepatic selective internal radiotherapy with yttrium-90 microspheres were retrospectively reviewed...
2013: ISRN Oncology
https://www.readbyqxmd.com/read/23846914/biomarkers-for-pancreatic-cancer-is-it-ready-for-primetime
#15
EDITORIAL
Richard Kim, Amit Mahipal, Minsig Choi, Mohammad Wasif Saif
No abstract text is available yet for this article.
July 2013: JOP: Journal of the Pancreas
https://www.readbyqxmd.com/read/23764501/geographic-differences-in-approach-to-advanced-gastric-cancer-is-there-a-standard-approach
#16
REVIEW
Richard Kim, Ann Tan, Minsig Choi, Bassel F El-Rayes
Gastric cancer is one of the leading causes of cancer related deaths worldwide. Regional differences in gastric cancer are evident between Asian and Western societies with respect to etiology, prevalence, clinicopathologic features as well as treatment pattern of the disease. For patients with advanced gastric cancer (AGC), chemotherapy has been found to improve survival and quality of life compared to best supportive care alone. But contrast to other tumors such as colon or pancreatic cancer, there are regional differences in outcome in gastric cancer...
November 2013: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/22406591/what-options-are-available-for-refractory-pancreatic-cancer
#17
REVIEW
Minsig Choi, Richard Kim, Muhammad Wasif Saif
Currently gemcitabine-based regimens and FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) are widely used standard for first-line treatment of patients with advanced pancreatic adenocarcinoma. Refractory patients may receive either FOLFOX (5-fluorouracil and oxaliplatin) or gemcitabine based on the first line regimen. This review is an update from the 2012 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium regarding recent developments in the treatment of refractory pancreatic cancer, as these were presented in Abstracts #248 and #373 of the meeting...
March 2012: JOP: Journal of the Pancreas
https://www.readbyqxmd.com/read/21683826/surveillance-and-monitoring-of-adult-cancer-survivors
#18
Minsig Choi, Barbara Craft, Stephen A Geraci
Advances in early detection and treatment have improved survival in common adult cancers. Surveillance for late recurrence and secondary primary malignancies is recommended for most patients. Initial treatment with surgery, radiation, chemotherapy, or hormonal therapy can result in both local and systemic sequelae, including treatment-related new cancers. Patients with head and neck, lung, breast, colorectal, and prostate cancers constitute the largest groups requiring long-term monitoring and follow-up care...
July 2011: American Journal of Medicine
https://www.readbyqxmd.com/read/21623005/network-modeling-of-mdm2-inhibitor-oxaliplatin-combination-reveals-biological-synergy-in-wt-p53-solid-tumors
#19
Asfar S Azmi, Sanjeev Banerjee, Shadan Ali, Zhiwei Wang, Bin Bao, Frances W J Beck, Main Maitah, Minsig Choi, Tony F Shields, Philip A Philip, Fazlul H Sarkar, Ramzi M Mohammad
Earlier we had shown that the MDM2 inhibitor (MI-219) belonging to the spiro-oxindole family can synergistically enhance the efficacy of platinum chemotherapeutics leading to 50% tumor free survival in a genetically complex pancreatic ductaladenocarcinoma (PDAC) xenograft model. In this report, we have taken a systems and network modeling approach in order to understand central mechanisms behind MI219-oxaliplatin synergy with validation in PDAC, colon and breast cancer cell lines. Microarray profiling of drug treatments (MI-219, oxaliplatin or their combination) in capan-2 cells reveal a similar unique set of gene alterations that is duplicated in other solid tumor cells...
May 2011: Oncotarget
https://www.readbyqxmd.com/read/19823097/preclinical-studies-of-apogossypolone-a-novel-pan-inhibitor-of-bcl-2-and-mcl-1-synergistically-potentiates-cytotoxic-effect-of-gemcitabine-in-pancreatic-cancer-cells
#20
Sanjeev Banerjee, Minsig Choi, Amro Aboukameel, Zhiwei Wang, Mussop Mohammad, Jianyong Chen, Dajun Yang, Fazlul H Sarkar, Ramzi M Mohammad
OBJECTIVE: Overexpression of antiapoptotic Bcl-2 family proteins confers resistance to conventional therapy in pancreatic cancer patients. Apogossypolone (ApoG2) is an analogue of (-)-gossypol, exhibiting binding activity with Ki values of 35 nmol/L for Bcl-2 and 25 nmol/L for Mcl-1. The present study was designed to test our hypothesis whether inactivation of Bcl-2 family of proteins using ApoG2 could sensitize pancreatic cancer cells to the cytotoxic effect of gemcitabine. METHODS: Two pancreatic cancer cell lines were treated with ApoG2, gemcitabine, and their combination; cytotoxicity and apoptosis was confirmed by MTT and histone/DNA enzyme-linked immunosorbent assay...
April 2010: Pancreas
keyword
keyword
68642
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"